Regeneron Pharmaceuticals Stock Discussion

Morning Movers
Gapping Up
$Hims & Hers Health (HIMS.US)$ Hims & Hers surged 34.1% and $Novo-Nordisk A/S (NVO.US)$ increased by 4%. This followed Novo Nordisk's announcement that it will broaden the availability of its weight loss drug Wegovy by offering it through telehealth providers Hims & Hers Health, Ro, and Life MD, now that the drug is no longer facing shortages in the U.S.
$SoFi Technologies (SOFI.US)$ stock rose 5.9% after...

$Regeneron Pharmaceuticals (REGN.US)$
Breakthrough: FDA Clears Dupixent for 300,000 Chronic Urticaria Patients After Decade-Long Wait

$Regeneron Pharmaceuticals (REGN.US)$ Sold my trading position at 734. Put a limit buy order at around 600 to wait for the gap fill. The 200 week moving average is a key resistance. The company has to prove the Eylea franchise revenue will not be significantly eroded by biosimilars.

$Regeneron Pharmaceuticals (REGN.US)$
Can Dupixent Transform Rare Skin Disease Treatment? New Trial Data Reveals Breakthrough

$Regeneron Pharmaceuticals (REGN.US)$ higher low?

$Regeneron Pharmaceuticals (REGN.US)$
Regeneron's Multiple Myeloma Drug Clears Critical EU Regulatory Hurdle - What's Next?

$Regeneron Pharmaceuticals (REGN.US)$
Can Regeneron's Cancer Drug With 80% Response Rate Secure FDA Approval For Lymphoma?

$Regeneron Pharmaceuticals (REGN.US)$
Revolutionary Hearing Breakthrough: Can This Gene Therapy End Childhood Genetic Deafness?

$Regeneron Pharmaceuticals (REGN.US)$ In traditional technical analysis, you would think this is likely reversed given the engulfing pattern with strong volume at an earnings event. But in this trending market, a higher high has to be established.